Priya Rastogi
A5002068827- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Metabolism, Diabetes, and Cancer
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- Prostate Cancer Treatment and Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer-related cognitive impairment studies
- Chronic Lymphocytic Leukemia Research
- Cancer, Lipids, and Metabolism
- Economic and Financial Impacts of Cancer
University of Pittsburgh
2016-2025
NSABP Foundation
2016-2025
Cancer Clinic
2009-2025
National Cancer Institute
2006-2025
National Center for Tumor Diseases
2025
Helios Hospital Berlin-Buch
2012-2025
Magee-Womens Hospital
2013-2024
NRG Oncology
2015-2024
UPMC Hillman Cancer Center
2015-2024
University of Pittsburgh Medical Center
2014-2023
Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy a worse prognosis than those no cancer. Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent (DM1), maytansine derivative microtubule inhibitor, provides benefit in patients with metastatic that was previously treated HER2-targeted therapy.
National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) overall (OS) compared with AC postoperatively. B-27 the effect adding docetaxel (T) preoperative on tumor response rates, DFS, OS.Analyses were limited eligible patients. In B-18, 751 patients assigned receive AC, 742 postoperative AC. B-27, 784 followed by...
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
Purpose Positive interim analysis findings from four large adjuvant trials evaluating trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2) –positive breast cancer were first reported 2005. One of these reports, the joint North Central Cancer Treatment Group NCCTG N9831 (Combination Chemotherapy With or Without Trastuzumab Treating Women HER2-Overexpressing Breast Cancer) and National Surgical Adjuvant Bowel Project NSABP B-31 (Doxorubicin Cyclophosphamide...
Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin cyclophosphamide (AC) followed by paclitaxel AC plus 52 weeks trastuzumab beginning concurrently patients node-positive, HER2-positive cancer. Initiation required normal post-AC left ventricular ejection...
Purpose Cardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer, especially when treatment regimen includes anthracyclines. Given demonstrated efficacy trastuzumab, ongoing assessment cardiac safety and identification factors CD are important optimal patient care. Patients Methods In National Surgical Adjuvant Breast Bowel Project B-31, phase III trial, 1,830...
Bevacizumab and the antimetabolites capecitabine gemcitabine have been shown to improve outcomes when added taxanes in patients with metastatic breast cancer. The primary aims of this trial were determine whether addition or neoadjuvant chemotherapy docetaxel, followed by doxorubicin plus cyclophosphamide, would increase rates pathological complete response women operable, human epidermal growth factor receptor 2 (HER2)–negative cancer adding bevacizumab these regimens response.
Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant currently available standard therapies. However, up to 30% of high-risk clinical and/or pathologic features may recurrence, many in the first few years. Superior treatment options are needed prevent and development metastases for this group patients. Abemaciclib is an oral, continuously dosed, CDK4/6 inhibitor approved advanced (ABC). Efficacy safety abemaciclib ABC supported evaluation...
PURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of the landmark adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective NSABP B-47 trial was determine whether addition chemotherapy (CRx) would improve disease-free survival (IDFS) cancer. PATIENTS AND METHODS total 3,270 women...
Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential is not known.We randomly assigned 5351 patients operable, node-positive, early-stage cancer to receive four cycles doxorubicin cyclophosphamide followed by docetaxel (sequential ACT); (doxorubicin-docetaxel); or doxorubicin, cyclophosphamide, (concurrent ACT). primary aims...
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free (DRFS) hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of prespecified primary outcome analysis an additional analysis.This global, phase III,...
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
Primary analyses of the phase III BrighTNess trial showed addition carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from trial.Women untreated stage II-III TNBC were randomized (2 : 1 1) paclitaxel (weekly for 12 doses) plus: (i) (every 3 weeks four cycles) plus (twice daily); (ii) placebo; or...
<h3>Importance</h3> Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes in observational and preclinical studies. <h3>Objective</h3> To determine whether the administration of adjuvant metformin (vs placebo) patients without diabetes improves outcomes. <h3>Design, Setting, Participants</h3> MA.32, phase 3 randomized, placebo-controlled, double-blind trial, conducted Canada, Switzerland, US, UK,...
In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at median follow-up 27 months and key patient-reported outcomes (PROs) are presented.The population included all patients who received least one dose study (n = 5591). Safety...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted a significant improvement invasive...
The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall (OS) in patients with early breast cancer (EBC), adapting postneoadjuvant therapy improves long-term outcomes HER2-positive disease not achieving pCR. We sought to investigate factors EFS OS among without pCR after neoadjuvant systemic treatment consisting chemotherapy plus anti-HER2 therapy.We used individual data from 3,710 randomly assigned 11 trials EBC ≥100 enrolled,...
BackgroundPatients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis KATHERINE, phase 3, open-label trial, showed that the or death was 50% lower adjuvant trastuzumab emtansine (T-DM1) than alone.MethodsWe randomly assigned patients HER2-positive in axilla treatment taxane-based chemotherapy to receive T-DM1 for 14 cycles. Here, we report...